Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $18.9300 (-4.35%) ($18.8800 - $19.8800) on Thu. Sep. 3, 2015. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.76% (three month average) | RSI | 29 | Latest Price | $18.9300(-4.35%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.2% a day on average for past five trading days. | Weekly Trend | ADMS declines -2.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(34%) IBB(32%) ARKG(23%) IWO(23%) IWM(22%) | Factors Impacting ADMS price | ADMS will decline at least -1.88% in a week (0% probabilities). VIXM(-14%) BNDX(-10%) TLT(-8%) SHY(-7%) UUP(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.88% (StdDev 3.76%) | Hourly BBV | 0 () | Intraday Trend | -4.8% | | | |
|
Resistance Level | $20.82 | 5 Day Moving Average | $19.79(-4.35%) | 10 Day Moving Average | $19.7(-3.91%) | 20 Day Moving Average | $20.82(-9.08%) | To recent high | -36.5% | To recent low | 0.1% | Market Cap | $535m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |